benserazide has been researched along with Herpes Zoster in 1 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
Herpes Zoster: An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty-seven outpatients with herpes zoster, seen within five days of onset of the eruption, received ten days' administration of oral levodopa and benserazide or placebo in a double-blind controlled study." | 9.05 | Administration of levodopa for relief of herpes zoster pain. ( Hauchecorne, J; Kernbaum, S, 1981) |
| "Forty-seven outpatients with herpes zoster, seen within five days of onset of the eruption, received ten days' administration of oral levodopa and benserazide or placebo in a double-blind controlled study." | 5.05 | Administration of levodopa for relief of herpes zoster pain. ( Hauchecorne, J; Kernbaum, S, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kernbaum, S | 1 |
| Hauchecorne, J | 1 |
1 trial available for benserazide and Herpes Zoster
| Article | Year |
|---|---|
Administration of levodopa for relief of herpes zoster pain.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; | 1981 |